Royalty Pharma
$57.63Change from previous close: −1.25%Absolute change: −$0.73
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $33.3B
- Enterprise value
- $36.74B
- P/E (trailing 12 months)
- 31.3
- Forward P/E
- 10.1
- PEG
- 1.36
- Price/book
- 3.71
- Price/sales
- 13.1
- EV/EBITDA
- 23.6
- EV/revenue
- 14.5
Profitability and growth
- Gross margin
- 95.8%
- Operating margin
- 19.7%
- Net margin
- 32.0%
- ROE
- 14.0%
- ROA
- 5.1%
- Revenue growth (year over year)
- 16.5%
- Earnings growth (year over year)
- -46.3%
Financial health
- Total cash
- $836.99M
- Total debt
- $8.96B
- Debt/equity
- 0.92
- Current ratio
- 2.80
- Quick ratio
- 2.79
Dividends
- Annual dividend per share
- $0.94
- Dividend yield
- 1.6%
- Payout ratio
- 48.9%
- Ex-dividend date
- August 14, 2026
Analysts and estimates
- Average price target
- $65.13
- Median price target
- $65.50
- High price target
- $70.00
- Low price target
- $61.00
- Analysts with a price target
- 8
- Forward EPS
- $5.73
- EPS estimate, current year
- $5.34
Shares and trading
- Beta
- 0.43
- Average volume
- 2.92M
- Shares outstanding
- 445.28M
- Float
- 417.57M
- Institutional ownership
- 87.3%
- Insider ownership
- 6.5%
- Short interest (% of float)
- 2.7%
- Short ratio (days)
- 3.89